Riskpilot← Back to searchSign inGet full accessASCENDIS PHARMA BONE DISEASES A/S
A/SActiveCVR 32323596Tuborg Boulevard 12Manufacture of pharmaceutical preparations · NACE 2120Est. 2012— employees
Revenue 2025
DKK 229,6M
-674981% vs 2024
EBITDA margin
68.6%
+145220% vs 2024
Equity ratio
-633.6%
Financial strength
Net profit 2025
DKK 135M
+97148% vs 2024
| Revenue | DKK 229,6M | -674981% |
| EBITDA | DKK 157,4M | +145220% |
| Net profit | DKK 135M | +97148% |
| Total assets | DKK 58,7M | +380543% |
| Equity | DKK -372,2M | -73285% |
| Employees | — | — |
Legal name
ASCENDIS PHARMA BONE DISEASES A/S
CVR number
32323596
Legal form
Aktieselskab
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
29. juni 2012
Share capital
DKK 500.000
Employees
—
VAT registered
Yes
Audit selected
Yes
Last report
2025-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af bestyrelsens formand i forening med en direktør eller af tre medlemmer af bestyrelsen.
Company purpose
Selskabets formål er at udvikle ideer og præparater til sygdomsbekæmpelse ad medicinsk vej, at producere og sælge sådanne præparater eller ideer, at eje aktier i selskaber med samme formål samt at udøve virksomhed, som står i naturlig forbindelse hermed.
Address
Tuborg Boulevard 12
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | -4.105 | -1.220 | -137 | -6.445 | -16.158 | -18.882 | -27.476 | -38.797 | -57.982 | -66.598 | -112.332 | -34 | 229.581 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -3 | -4.115 | -1.309 | -222 | -6.532 | -16.245 | -18.976 | -27.593 | -38.913 | -58.098 | -66.715 | -112.363 | -108 | 157.422 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -3 | -4.115 | -1.309 | -222 | -6.532 | -16.245 | -18.976 | -27.593 | -38.913 | -58.098 | -66.715 | -112.363 | -108 | 157.422 |
| Net financials | 0 | 0 | -28 | -57 | -102 | -379 | -869 | -1.543 | -2.469 | -3.868 | -5.585 | -6.781 | -31 | -22.388 |
| Profit before tax | -3 | -4.115 | -1.337 | -279 | -6.634 | -16.624 | -19.845 | -29.136 | -41.382 | -61.966 | -72.299 | -119.143 | -140 | 135.034 |
| Tax | -0 | -0 | -0 | -1 | -13 | -0 | -0 | -318 | -82 | -141 | -102 | -187 | -1 | 52 |
| Net profit | -3 | -4.115 | -1.337 | -279 | -6.621 | -16.624 | -19.845 | -28.818 | -41.300 | -61.825 | -72.198 | -118.957 | -139 | 134.982 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 122 | 2.314 | 615 | 241 | 1.338 | 3.216 | 13.468 | 14.856 | 18.140 | 18.339 | 18.541 | 39.609 | 15 | 58.737 |
| Equity | 122 | -3.993 | -1.661 | -1.939 | -8.560 | -25.184 | -45.029 | -73.847 | -115.147 | -176.972 | -249.170 | -368.127 | -507 | -372.183 |
| Long-term debt | 0 | 0 | 0 | 2.175 | 9.397 | 27.288 | 50.202 | 85.190 | 128.547 | 195.305 | 267.705 | 407.729 | 519 | 398.585 |
| Short-term debt | 0 | 6.307 | 2.276 | 5 | 502 | 1.113 | 8.295 | 3.513 | 4.740 | 6 | 6 | 7 | 4 | 32.335 |
| Total debt | 0 | 6.307 | 2.276 | 2.180 | 9.899 | 28.401 | 58.497 | 88.703 | 133.287 | 195.311 | 267.711 | 407.736 | 523 | 430.920 |
EBITDA margin
68.6%
This company
15.8%
Market median
+334% vs market
20122025
Equity ratio
-633.6%
This company
38.2%
Market median
-1759% vs market
20122025
Return on equity
13498200000.0%
This company
18.4%
Market median
+73359782509% vs market
20122025
Net profit margin
58.8%
This company
8.1%
Market median
+626% vs market
20122025
Asset turnover
3.91×
This company
1.12×
Market median
+249% vs market
20122025
Debt / equity
1.16×
This company
0.62×
Market median
-87% vs market
20122025
- Annual report 2025Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-06-29 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
JM Chief Executive Officer | Chief Executive Officer | 2012 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2012 | — | — | |
| Board of Directors | 2012 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
ASCENDIS PHARMA A/S | Company | 100.0% | 100.0% | 2012 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
ASCENDIS PHARMA A/S
ASCENDIS PHARMA BONE DISEASES A/S Board members of ASCENDIS PHARMA BONE DISEASES A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jan Møller Mikkelsen | Chief Executive Officer | 0 companies |
| Michael Wolff Jensen | Chairman | 0 companies |
| Anni Lotte Kirstine Pedersen | Board of Directors | 0 companies |